ClinicalTrials.gg
TerminatedNCT06597656HORIZONUpdated Sep 4, 2025

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

A Phase 1 interventional study of delandistrogene moxeparvovec and Plasmapheresis in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Terminated at 3 sites in United States. Open to male participants aged 4 Years to 8 Years. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Study is being terminated due to a business decision.

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
4 Years to 8 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
25th of 25
3 · median 24
Started
2024
with 2 others
Phase 1
5 of 27
1 open now
Registered
26th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 25th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 1, and was the 26th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 8 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

This is a gene transfer therapy study evaluating the safety of and delandistrogene moxeparvovec dystrophin protein expression from delandistrogene moxeparvovec following therapeutic plasma exchange (plasmapheresis) in ambulatory male participants with DMD and pre-existing antibodies to AAVrh74 over a period of 59 weeks.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Gene-Delivery
  • DMD
  • Ambulatory
  • Pediatric
  • Duchenne
  • Seropositive
  • Pre-existing antibodies
  • AAVrh74 antibody
  • Plasmapheresis
  • Titer
  • Seropositivity
04

Who can participate

Ages eligible
4 Years to 8 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory per protocol specified criteria.
  • Has a definitive diagnosis of DMD prior to Screening based on documentation of clinical findings and prior confirmatory genetic testing.
  • Ability to cooperate with motor assessment testing.
  • Has elevated AAVrh74 antibody titers per protocol-specified requirements.
  • A pathogenic frameshift mutation, nonsense mutation or premature stop codon or pathogenic variant in the DMD gene that is expected to lead to absence of dystrophin protein with exception of a mutation in exon 8 and/or 9.
  • Stable daily dose of oral for at least 12 weeks prior to Screening, and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight).

Exclusion criteria

Exclusion Criteria:

  • Has reduced on the screening ECHO or clinical signs and/or symptoms of cardiomyopathy.
  • Presence of any other illness, including cardiac, pulmonary, hepatic, renal, hematologic, immunologic, or behavioral disease, or infection or or concomitant illness or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risks for gene transfer or a medical condition or extenuating circumstance that, in the opinion of the Investigator, might compromise the participant's ability to comply with the protocol required testing or procedures or compromise the participant's wellbeing, safety, or clinical interpretability.
  • Exposure to gene therapy, medication, or other protocol-specified treatment within the protocol specified time limits.
  • Abnormality in protocol-specified diagnostic evaluations or laboratory tests. .

Note: Other inclusion or exclusion criteria could apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Delandistrogene Moxeparvovec After Plasmapheresis Procedure

    Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1 after plasmapheresis procedure if AAVrh74 antibodies are sufficiently low.

    Genetic: delandistrogene moxeparvovec · Procedure: Plasmapheresis

Interventions

  • Geneticdelandistrogene moxeparvovec

    Single IV infusion of delandistrogene moxeparvovec

    Also known as: SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS

  • ProcedurePlasmapheresis

    Therapeutic plasma exchange procedure

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression Adjusted by Muscle Content Biopsied Muscle as Measured by Western Blot

    Time frame: Baseline, Week 12

  2. Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression in Biopsied Muscle as Measured by Immunofluorescence (IF) Fiber Intensity

    Time frame: Baseline, Week 12

  3. Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression in Biopsied Muscle as Measured by IF Percent Dystrophin-positive Fibers (PDPF)

    Time frame: Baseline, Week 12

  4. Mean Concentration of Vector Genome Copies Using Polymerase Chain Reaction in Muscle Tissue Biopsy, After Delandistrogene Moxeparvovec Administration

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants with a Treatment Emergent Adverse Event (TEAE), Adverse Event of Special Interest (AESI), and Serious Adverse Event (SAE)

    Time frame: Baseline up to End of Study (Up to Week 59)

  2. Change from Baseline in rAAVrh74 Antibody Titers

    Time frame: Baseline, Week 1

07

Study locations

3 sites
  • University of Florida, College of Medicine
    Gainesville, Florida 32610, United States
  • Washington University School of Medicine in St. Louis
    St Louis, Missouri 63110, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Aug 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Sep 19, 2024
StartActual
Sep 18, 2024
Primary completionActual
Aug 5, 2025
CompletionActual
Aug 5, 2025
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06597656
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 18, 2024
Primary completion
Aug 5, 2025
Completion
Aug 5, 2025
Last update
Sep 4, 2025

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion